BioFire® FilmArray® Respiratory Plus Assay at Chughtai Lab

BioFire® FilmArray® Respiratory Plus Assay at Chughtai Lab

The BioFire® FilmArray® Respiratory Plus Assay at Chughtai Lab is a state-of-the-art molecular diagnostic test designed to rapidly and accurately identify a comprehensive panel of respiratory pathogens. Utilizing advanced multiplex Polymerase Chain Reaction (PCR) technology, this syndromic diagnostic tool can simultaneously detect and identify the genetic material of multiple viruses and bacteria associated with respiratory tract infections from a single nasopharyngeal swab. In clinical environments where time is of the essence, such as intensive care units, emergency departments, and pediatric wards, this assay provides critical diagnostic clarity within hours, rather than the days required for traditional viral cultures or bacterial assays.

Respiratory infections present with highly overlapping clinical symptoms, making it exceptionally challenging for healthcare providers to differentiate between viral pathogens like Influenza, Respiratory Syncytial Virus (RSV), and SARS-CoV-2, or bacterial pathogens like Mycoplasma pneumoniae and Bordetella pertussis based on clinical presentation alone. The BioFire® FilmArray® Respiratory Plus Assay solves this diagnostic dilemma by offering a syndromic approach. By testing for a broad spectrum of potential pathogens at once, the assay eliminates the need for sequential, single-pathogen testing, thereby saving valuable clinical time, reducing healthcare costs, and optimizing patient management strategies across Pakistan.

At Chughtai Lab, this molecular assay is performed using the highly sophisticated BioFire® FilmArray® System by bioMérieux. The system integrates sample preparation, nucleic acid extraction, nested multiplex PCR amplification, and detection into a single, automated closed-loop pouch. This minimizes the risk of laboratory contamination and ensures the highest levels of sensitivity and specificity. By identifying the specific causative agent of a respiratory illness rapidly, clinicians can make timely decisions regarding appropriate antiviral or antibiotic therapy, implement necessary infection control measures, and avoid the unnecessary administration of broad-spectrum antibiotics, thereby contributing to global antimicrobial stewardship efforts.

Clinical Procedure: What to Expect

Patient Preparation

The BioFire® FilmArray® Respiratory Plus Assay requires minimal patient preparation, making it highly convenient for acutely ill patients, pediatric cases, and elderly individuals. To ensure accurate results, please observe the following guidelines:

• No Fasting Required: There is no need to fast before the test. Patients can eat, drink, and take their regular medications as prescribed.
• Avoid Nasal Sprays: Patients should avoid using medicated nasal sprays, drops, or nasal washes for at least 4 to 6 hours prior to sample collection, as these substances may interfere with the PCR amplification process.
• Inform the Clinician: Inform the sample collection staff about any recent nasal surgeries, deviated septum, or active nosebleeds, as this helps them select the most appropriate nostril for swab insertion.
• No Special Attire: No specific clothing is required, though comfortable attire is recommended for ease during the quick collection process.

During the Procedure

The sample collection for the BioFire® FilmArray® Respiratory Plus Assay is a straightforward, standardized procedure performed by trained phlebotomists or clinical staff at Chughtai Lab:

• Patient Positioning: The patient is seated comfortably, and their head is tilted slightly backward to expose the nasal passages.
• Swab Selection: A specialized, sterile, flexible minitip flocked swab is used. This swab is specifically designed to collect cellular material from the nasopharyngeal mucosa efficiently.
• Sample Collection: The healthcare professional gently inserts the swab through the nostril parallel to the palate until resistance is met, indicating contact with the nasopharynx. The swab is gently rotated for several seconds to absorb secretions and collect epithelial cells, then carefully withdrawn.
• Sensation: The procedure may cause brief discomfort, a tickling sensation, or temporary tearing of the eyes, which subsides immediately after the swab is removed.
• Sample Preservation: The swab is immediately placed into a tube containing Viral Transport Medium (VTM) or Universal Transport Medium (UTM) to preserve the viral and bacterial nucleic acids.
• Laboratory Processing: The sample is transported to the molecular diagnostics department of Chughtai Lab. The technician injects the sample into the BioFire® reagent pouch, which is then placed into the FilmArray® instrument. The automated run takes approximately 45 to 60 minutes, during which the system extracts, amplifies, and analyzes the pathogen DNA/RNA.

When is a BioFire® FilmArray® Respiratory Plus Assay Performed?

Severe Acute Respiratory Infections (SARI)

Physicians request the BioFire® Respiratory Plus Assay when a patient presents with severe acute respiratory symptoms, such as high fever, rapid breathing, severe cough, and hypoxia. In these critical cases, identifying whether the infection is viral (e.g., severe Influenza or COVID-19) or bacterial (e.g., atypical pneumonia) is vital for immediate therapeutic intervention and life-support planning.

Atypical Pneumonia and Bacterial Infections

When standard bacterial cultures fail to identify a pathogen in patients suspected of having atypical pneumonia, this assay is highly valuable. It detects fastidious bacterial pathogens like Mycoplasma pneumoniae and Chlamydia pneumoniae, which are difficult to culture in standard laboratory settings, allowing doctors to prescribe targeted macrolide or tetracycline therapy promptly.

Influenza-Like Illness (ILI) in Vulnerable Patients

For high-risk populations—including elderly individuals, patients with chronic obstructive pulmonary disease (COPD), asthma, or congestive heart failure—an influenza-like illness can rapidly deteriorate into respiratory failure. Performing this rapid multiplex PCR assay helps clinicians differentiate between seasonal flu, RSV, and other pathogens, enabling the timely administration of targeted antivirals like Oseltamivir.

Pediatric Respiratory Distress

Infants and young children are highly susceptible to severe respiratory tract infections caused by RSV, Human Metapneumovirus, and Adenovirus. Because pediatric patients can deteriorate quickly, pediatricians rely on the rapid turnaround time of the BioFire® assay at Chughtai Lab to confirm the viral etiology, manage supportive care, and prevent unnecessary antibiotic use in young children.

Immunocompromised Patient Screening

Patients undergoing chemotherapy, transplant recipients on immunosuppressive drugs, and individuals with advanced HIV are at extreme risk for severe complications from common respiratory viruses. This assay is performed at the earliest sign of respiratory symptoms in these patients to identify pathogens like Parainfluenza or Rhinovirus, which can cause devastating lower respiratory tract disease in immunocompromised hosts.

What Does a BioFire® FilmArray® Respiratory Plus Assay Detect?

The BioFire® FilmArray® Respiratory Plus Assay is designed to detect a comprehensive panel of viral and bacterial targets. These include:

• Adenovirus: A common cause of respiratory tract infections, conjunctivitis, and gastroenteritis, particularly in children.
• Coronavirus 229E: One of the seasonal coronaviruses responsible for mild to moderate upper respiratory tract infections.
• Coronavirus HKU1: A seasonal coronavirus associated with common cold symptoms and occasionally lower respiratory tract complications.
• Coronavirus NL63: A viral pathogen linked to bronchiolitis and croup in pediatric patients.
• Coronavirus OC43: A common seasonal coronavirus causing upper respiratory tract illnesses.
• Middle East Respiratory Syndrome Coronavirus (MERS-CoV): A high-consequence zoonotic coronavirus causing severe respiratory disease.
• SARS-CoV-2: The causative agent of COVID-19, critical for infection control and clinical management.
• Human Metapneumovirus (hMPV): A significant cause of bronchiolitis and pneumonia in children and elderly individuals.
• Human Rhinovirus/Enterovirus: Highly prevalent viruses responsible for the common cold, asthma exacerbations, and severe respiratory illness in high-risk patients.
• Influenza A: A major cause of seasonal epidemics, associated with high morbidity and mortality in vulnerable populations.
• Influenza A/H1: A specific subtype of Influenza A virus.
• Influenza A/H3: A subtype of Influenza A often associated with more severe flu seasons in the elderly.
• Influenza A/H1-2009: The pandemic strain of Influenza A (swine flu).
• Influenza B: A seasonal influenza virus that causes significant respiratory disease epidemics.
• Parainfluenza Virus 1: A primary viral cause of croup (laryngotracheobronchitis) in young children.
• Parainfluenza Virus 2: Associated with croup and upper respiratory tract infections.
• Parainfluenza Virus 3: Frequently linked to bronchiolitis and pneumonia in infants.
• Parainfluenza Virus 4: Associated with mild to moderate upper respiratory tract infections.
• Respiratory Syncytial Virus (RSV): The leading cause of bronchiolitis and pneumonia in infants and young children globally.
• Bordetella parapertussis: A bacterium that causes a pertussis-like illness (whooping cough), typically milder than B. pertussis.
• Bordetella pertussis: The causative agent of whooping cough, a highly contagious and potentially life-threatening bacterial infection.
• Chlamydia pneumoniae: An atypical bacterium causing bronchitis and community-acquired pneumonia.
• Mycoplasma pneumoniae: A common bacterial cause of “walking pneumonia” in school-aged children and young adults.

Turnaround Time and Report Access at Chughtai Lab

Chughtai Lab is committed to providing rapid and reliable diagnostic results. Because the BioFire® FilmArray® Respiratory Plus Assay is an automated, closed-system molecular test, the laboratory processing time is highly optimized. Typically, results are verified by expert molecular pathologists and made available within a few hours of the sample reaching the main molecular diagnostic facility.

Patients and referring physicians can access reports seamlessly through multiple digital channels provided by Chughtai Lab. Once the report is finalized, an automated SMS notification is sent to the patient’s registered mobile number. Reports can be viewed, downloaded, and printed via the official Chughtai Lab website portal or the user-friendly Chughtai Lab Mobile App. Additionally, patients can receive their reports directly on WhatsApp or collect a high-quality printed copy from any of the numerous Chughtai Lab collection centers located across Pakistan.

BioFire® FilmArray® Respiratory Plus Assay Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Influenza Viruses (A, A/H1, A/H3, A/H1-2009, B)	Not Detected	Detected (Indicates active Influenza infection; guides antiviral therapy)
SARS-CoV-2	Not Detected	Detected (Confirms active COVID-19 infection; mandates isolation and monitoring)
Respiratory Syncytial Virus (RSV)	Not Detected	Detected (Indicates active RSV infection; critical for pediatric management)
Adenovirus & Human Metapneumovirus	Not Detected	Detected (Confirms viral etiology of upper/lower respiratory tract infection)
Human Rhinovirus/Enterovirus	Not Detected	Detected (Identifies common cold or trigger for asthma/COPD exacerbation)
Parainfluenza Viruses (1, 2, 3, 4)	Not Detected	Detected (Associated with croup, bronchitis, or pediatric respiratory distress)
Mycoplasma pneumoniae	Not Detected	Detected (Confirms atypical bacterial pneumonia; indicates antibiotic therapy)
Bordetella pertussis / parapertussis	Not Detected	Detected (Confirms whooping cough; requires immediate antibiotic treatment and isolation)
Chlamydia pneumoniae	Not Detected	Detected (Indicates atypical bacterial respiratory infection)

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Chughtai Lab for BioFire® FilmArray® Respiratory Plus Assay?

• Experienced Healthcare Professionals: Chughtai Lab employs highly qualified molecular biologists and consultant pathologists who oversee all PCR testing procedures.
• Patient-Focused Care: The lab provides a compassionate, patient-centric environment, ensuring comfort during the nasopharyngeal swab collection.
• Quality Diagnostic Services: Chughtai Lab adheres to stringent international quality control standards, participating in external quality assurance programs.
• Professional Reporting: Reports are detailed, clear, and structured to provide actionable diagnostic insights for referring physicians.
• Modern Diagnostic Approach: Utilizing the advanced bioMérieux BioFire® FilmArray® system ensures cutting-edge syndromic testing capabilities.
• Comfortable Environment: All collection centers are designed to be clean, hygienic, and welcoming for patients of all ages.
• Convenient Location: With a vast network of collection centers across Pakistan, patients can easily access testing services close to home.
• Commitment to Accurate Diagnosis: Chughtai Lab’s advanced molecular setup minimizes false positives and negatives, delivering trustworthy results when they matter most.